Medxbio is a Singapore based Biopharmaceutical company acting globally in the development and commercialization of high value Biopharmaceuticals and Medical Devices. We aim to improve qualities of products and life of patients by introducing inventive solutions and improved technologies in the healthcare space. Current Biopharmaceuticals portfolio include: --BIOLOGICALS-- NON-THERAPEUTIC Recombinant Albumin Recombinant Trypsin Recombinant Carboxypeptidase B Recombinant Enterokinase Non-therapeutic Human Insulin Recombinant Protein - A Recombinant Lipase - A Recombinant Hyaluronidase THERAPEUTIC Recombinant Human Insulin Recombinant Insulin Analogues Recombinant Interferons Recombinant Filgrastim Recombinant Somatropin Recombinant Erythropoietin Monoclonal Antibodies --PHARMACEUTICALS-- Our portfolio include over 100 products in most therapeutic categories. Medxbio pharmaceuticals are manufactured in Europe and comply with EU cGMP and have EU CTD Dossiers. The products are suitable or commercialization in most countries, affordable high quality generic and innovative drug products. --MEDICAL DEVICES-- Our Medical Device range includes new formulations, patented and innovative pharmaceuticals registered under Medical Device classes. Most of Medxbio Medical Device have CE and / or FDA compliance. The Medical Device range corresponds to a large variety of therapeutic classes. For more information about our portfolio please visit Medxbio website: www.medxbio.com